The study is a prospective open escalating dose Phase I trial with PM01183 and Capecitabine in patients with unresectable metastatic breast cancer, pancreatic cancer, and metastatic colon cancer

breast cancer Financial terms were not disclosed 4/4/13 Debiopharm Group (Lausanne, Switzerland) Shasun Pharmaceuticals Ltd. (Channai, India) ND Licensing agreement for the manufacturing and commercialization of Huperzine-A Shasun will be able to use the Debiopharm technology to manufacture synthetic Huperzine-A under GMP quality conditions and commercialize it in pharmaceutical and nutraceutical markets 4/11/13 Eddingpharm (Hong Kong) GlaxoSmithKline plc (London) ND Collaboration in which to

The aim of the partnership was the better understanding of the mechanism of action of a new Roche antibody to target underserved highly aggressive forms of breast cancer

Early evidence of efficacy using MPDL3280A across a wide swath of solid tumors is especially encouraging given that Phase I studies traditionally focused on safety, said Clifford A. Hudis, president-elect of ASCO, chief of the breast cancer medicine service at Memorial Sloan-Kettering Cancer Center and professor of medicine at Weill Medical College of Cornell University

on the strategy for expanding Radium-223 development, importantly further studies in metastatic castrate-resistant prostate cancer (mCRPC), potentially in combination with oral Zytiga/Xtandi and/or in earlier stage patients, but also a possible Phase II trial in metastatic breast cancer

We believe this is a promising new lead for future breast cancer therapy...In breast cancer, however, although the cells' growth – normally driven by estrogen – was reduced, they did not die

Syndax Pharmaceuticals Inc., of Waltham, Mass., said Phase II results published in the Journal of Clinical Oncology showed that HDAC inhibitor entinostat extended both progression-free survival (PFS) and overall survival when added to exemestane in postmenopausal women with estrogen receptor-positive breast cancer whose cancer had progressed after treatment with a nonsteroidal aromatase inhibitor

breast cancer The final patient was enrolled in one group of a two-cohort Phase II trial of MM-121 combined with paclitaxel 4/16/13 Merrimack Pharmaceuticals Inc. (Cambridge, Mass.) MM-121 A signaling inhibitor targeting ErbB3 Non-small-cell lung cancer One cohort of a Phase II study did not meet its primary endpoints in combination with Tarceva 4/5/13 NewLink Genetics Corp. (Ames, Iowa) IDO Indoleamine-(2,3)-dioxygenase pathway inhibitor, indoximod Metastatic breast cancer Started a Phase II

The drug gained approval for patients with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy

Breast cancer Dosed the first patient in a Phase I trial 4/5/13 Emergent BioSolutions Inc. (Rockville, Md.) TRU-016 Humanized anti-CD37 monospecific protein therapeutic Chronic lymphocytic leukemia Expanded the Phase Ib trial to include two additional study cohorts to examine a lower dose of TRU-016 with rituximab 4/8/13 Senesco Technologies Inc. (Bridgewater, N.J.) SNS01-T Designed to selectively trigger apoptosis in B-cell cancers Multiple myeloma Completed the second cohort of its Phase Ib

In the breast cancer program, Galapagos has discovered a drug that completely blocks tumor growth in a mouse model of triple-negative breast cancer

In separate news, Eisai said it filed a Type II variation application with the European Medicines Agency for Halaven (eribuln), requesting an indication extension to include treatment of earlier-line metastatic breast cancer patients

The authors showed that through its recruitment of immune cells to the liver, the compound helped mice fight off liver metastases derived from cell lines of colon, lymphoma, and breast cancers

In February of this year, the FDA gave its nod to T-DM1, branded Kadcyla, which pairs Roche AG's Herceptin (trastuzumab) with ImmunoGen Inc.'s DM1 maytansinoid cell-killing agent in HER2-positive metastatic breast cancer. (See BioWorld Today, Aug. 22, 2011, and Feb. 25, 2013.) "We've been working on ADCs for a number of years, well before the approval of Adcetris and, more recently, Kadcyla," Allen said...Among the other ADC players is Celldex Therapeutics Inc., which in February raised $90 million

The addition of MEK- or RSK-specific inhibitors can overcome these resistance phenotypes, both in breast cancer cell lines and patient-derived xenograft models with elevated levels of RSK activity," they wrote

In the breast cancer program, Galapagos has discovered a drug that completely blocks tumor growth in a mouse model of triple negative breast cancer

GTx Inc., of Memphis, Tenn., said it is starting a proof-of-concept Phase II study to evaluate enobosarm (GTx-024), a selective androgen receptor modulator, in metastatic breast cancer

Last December, it began a Phase II trial in patients with triple-negative breast cancer, and the drug is in ongoing trials for metastatic colorectal cancer, soft-tissue sarcomas, hepatic impairment and metastatic RCC

placebo will include 50 pre-and postmenopausal women with Stage I-III breast cancer found on diagnostic core needle biopsy...Progesterone, like estrogen, has been implicated in the causation and progression of breast cancer, which led to the concept that an anti-progesterone therapy could reverse the effects of endogenous female hormones